DC Vaccine for Melanoma 
Protocol Version 9.08-10-2021 
Mature Dendritic Cell Vaccination Against Mutated Antigens 
in Patients with Advanced Melanoma 
Principal Investigator: 
Protocol Numbers: 
IND Number: Gerald Linette, MD, PhD 
Division of Hematology Oncology 
University of Penns lvania School of Medicine 
Telephone: 
E-mail: enn.edu 
cer Immunothera 
Penn IRB# 826433 Page 1 of 38 
Investigational Product: ntigen peptide-pulsed mature dendritic cell 
Cell Manufacturing: 
Next Generation 
Sequencing 
Related Test 
Conelative Laboratory 
Team: 
Biostatistician: 
Original Protocol Date: 
Amended: Vl: November 16, 2016 
V2: January 17, 2017 
V3: February 14, 2017 
V 4: June 5, 2017 
VS: November 10, 2017 
V6: June 27, 2018 
V7: December 7, 2018 
V8: October 13, 2020 
V9: August 10, 2021 • • • • uenza) 
---�----I 
CONFIDENTIAL 
This protocol is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor. NCT 03092453
DC Vaccine for Melan oma Page 2 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. S
chema  
C
onsent/Screen ing 
A
pheresis ( ~Day -7) 
CT
X 300 mg/m2 IV [D ay -3 (+/ - 1 day)] 
D
ay 1: DC Vaccine #1 ( Priming  vaccine dose) (mature DC 7.5- 15 million/peptide)  
B
ooster vaccine d oses (DC Vaccine #2 and DC Vaccine #3) (~q6w ) mDC ( 1-5 million/peptide)  
Re-st
aging after Last DC Vaccine/Tumor Biopsy /Apheresis 
An
ti-PD-1 therapy (standard of care)/Follow-up 
T
umor biops ies/Apheresis  
E
nd of Study 
*
Immune monitoring : Beginning on Day 1/Week 1  and collected weekly thereafter through Week 18
(~Day 120), the n every third  week for 12 additional weeks, for a total of 30 weeks.  Please refer to
Section 8.5 for additional details.  
*Immune Monitoring Sample  Collection
DC Vaccine for Melan oma Page 3 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. TABLE OF CONTENTS  
Schema  ......................................................................................................................................................... 2 
1.0 BACKGROUND AND RATIONALE  ......................................................................................... 6 
1.1 Overview  ................................................................................................................................ 6 
1.2 Chemotherapy for Melanoma ................................................................................................ 6 
1.3 Cytokines for Melanoma  ........................................................................................................ 6 
1.4 Vaccines for Melanoma ......................................................................................................... 6 
1.4.1  Gp100 Melanoma Antigen Vaccines .......................................................................... 7 
1.4.2  Melanoma Neoantigens  .............................................................................................. 7 
1.5 Dendritic Cells  ....................................................................................................................... 7 
1.6 Regulatory T Cells  ................................................................................................................. 8 
1.7 Study Rationale ...................................................................................................................... 8 
1.8 Investigational Product Update: September 2016  .................................................................. 8 
1.9 Major Study Update: November 2017 ................................................................................... 9 
2.0 OBJECTIVES  ................................................................................................................................ 9 
2.1 Primary Objective .................................................................................................................. 9 
2.2 Secondary Objectives  ............................................................................................................. 9 
3.0 ELIGIBILITY CRITERIA ......................................................................................................... 10 
3.1 Inclusion Criteria .................................................................................................................. 10 
3.2 Exclusion Criteria ................................................................................................................ 10 
4.0 REGISTRATION ........................................................................................................................ 11 
5.0 PATIENT RECRUITMENT AND SCREENING  .................................................................... 11  
6.0 CONCO M
ITANT THERAPY .................................................................................................... 12 
7.0 INVESTIGATIONAL PRODUCTS  .......................................................................................... 13 
7.1 Dendritic Cell Vaccines (mDC3/8 vaccines with and without influenza)  ........................... 13 
7.1.1  Agent Description  ..................................................................................................... 13 
7.1.2  Mechanism of Action  ............................................................................................... 13 
7.1.3  Pharmacodynamics/Kinetics ..................................................................................... 13 
7.1.4  Formulation .............................................................................................................. 13 
7.1.5  Availability  ............................................................................................................... 13 
7.1.6  Preparation  ................................................................................................................ 13 
7.1.7  Packaging and Labeling  ............................................................................................ 14 
7.1.8  Administration  .......................................................................................................... 14 
7.1.9  Potential Toxicities  ................................................................................................... 14 
7.1.10  Return or Destruction of Study Drug ........................................................................ 14 
7.2 Cyclophosphamide ............................................................................................................... 14 
7.2.1  Agent Description  ..................................................................................................... 14 
7.2.2  Receipt and Storage  .................................................................................................. 15 
7.2.3  Premedication  ........................................................................................................... 15 
7.2.4  Administration  .......................................................................................................... 15 
7.2.5  Potential Toxicities  ................................................................................................... 15 
7.3 Anti-PD-1 (Pembrolizumab) ................................................................................................ 15 
DC Vaccine for Melan oma Page 4 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 8.0 STUDY PROCEDURES  ............................................................................................................. 15 
8.1 On-study Biopsies ................................................................................................................ 15 
8.2 Dendritic Cell (mDC3/8) Preparation .................................................................................. 16 
8.3 Treg Depletion  ..................................................................................................................... 16 
8.4 Administration of Dendritic Cell Vaccines (mDC3/8 vaccines with and without 
influenza) ............................................................................................................................. 16 
8.5 Immune Monitoring ............................................................................................................. 17 
8.6 Assessment of Clinical Response  ......................................................................................... 17 
8.7 Anti-PD-1 Administration  .................................................................................................... 18 
9.0 POTENTIAL TOXICITY AND DOSE MODIFICATIONS  ................................................... 18 
9.1 Dose Limiting Toxicity  ........................................................................................................ 18 
10.0  STUDY CALENDAR  .................................................................................................................. 19 
11.0  CRITERIA FOR RESPONSE (RECIST Criteria v1.1)  ........................................................... 22 
11.1  Tumor Measurement  ............................................................................................................ 22 
11.2  Baseline Documentation of Target and Non -target Lesions  ................................................ 22 
11.3  Response Criteria ................................................................................................................. 23 
11.3.1  Evaluation of Target Lesions .................................................................................... 23 
11.3.2  Evaluation of Non- target Lesions  ............................................................................. 23 
11.4  Evaluation of Best Overall Response  ................................................................................... 23 
11.5  Confirmation ........................................................................................................................ 24 
12.0  EARLY WITHDRAWAL OF SUBJECTS  ............................................................................... 24 
13.0  SAFETY AND ADVERSE EVENTS  ......................................................................................... 25 
13.1  Definitions  ............................................................................................................................ 25 
13.2  Recording of Adverse Events ............................................................................................... 27 
13.3  Reporting of Serious Adverse Events .................................................................................. 28 
13.3.1  Investigator Reporting: Local Regulatory Review Committees  ............................... 29 
13.4  Pregnancies  .......................................................................................................................... 29  
13.5  Protocol Exceptions/Deviations ........................................................................................... 29 
13.6  Medical Monitoring ............................................................................................................. 30 
13.7  Study Stopping Rules ........................................................................................................... 30 
14.0  STATISTICAL CONSIDERATIONS  ....................................................................................... 30 
15.0  DATA HANDLING AND RECORDKEEPING  ....................................................................... 31 
15.1  Confidentiality  ..................................................................................................................... 31 
15.2  Source Documents ............................................................................................................... 32 
15.3  Case Report Forms ............................................................................................................... 32 
15.4  Records Retention  ................................................................................................................ 32 
16.0  STUDY MONITORING, AUDITING, AND INSPECTING  ................................................... 32 
16.1  Study Monitoring Plan ......................................................................................................... 32 
16.2  Auditing and Inspecting ....................................................................................................... 33 
DC Vaccine for Melan oma Page 5 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 17.0  ETHICAL CONSIDERATIONS  ................................................................................................ 33 
18.0  STUDY FINANCES ..................................................................................................................... 33 
18.1  Funding Source .................................................................................................................... 33 
18.2  Conflict of Interest ............................................................................................................... 34 
18.3  Patient Stipends or Payment s ............................................................................................... 34 
19.0  PUBLICATION PLAN  ............................................................................................................... 34 
20.0  REFERENCES  ............................................................................................................................. 35 
DC Vaccine for Melan oma Page 6 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 1.0 BACKGROUND AND RATIONALE 
1.1 Overview 
 In
 2016, it is estimated that 76,380 new cases of melanoma will be diagnosed in the US  (1). 
Although disease will be detected early and cured  in many individuals  with surgery, approximately 
10,130 patients will die from metastatic melanoma. Patients with metastatic (stage I V) melanoma 
suffer a poor prognosis . Since 2011, two new treatments have become available for patients with 
metastatic melanoma. Checkpoint inhibitors such as Ipilimumab , Nivolumab, and Pembrolizumab 
serve to block negative inhibitory signals during T  cell activation and allow tumor -specific T  cells 
to recognize and eliminate cancer.  The 3 approved checkpoint inhibitors have all been shown in 
randomized controlled trials to improve overall survival when compared to chemotherapy (2-4). 
The second new treatment targets the BRAF V600E mutation which is present in approximately 50% of patients with cutaneous melanoma. Vemurafenib is a selective oral inhibitor of the mutated 
(V600E) BRAF kinase. A randomized phase 3 controlled clinical trial demonstrated improved OS 
in patients receiving vemurafenib compared to dacarbazine  (5). Vemurafenib was approved in 
August 2011. In addition, the combination of a BRAF inhibitor plus a MEK inhibitor 
(dabrafenib/trametinib, GSK) was granted regulatory approval in 2014 based upon improved ORR 
and overall survival (6,7). Despite approval  of these new agents, metastatic melanoma remains an 
incurable malignancy with a median OS estimated at 24  months.   
1.2 Chemotherapy for Melanoma 
 C
hemotherapy has little impact on the natural history of metastatic melanoma. Dacarbazine 
received FDA approval in 1975 and remains  a treatment option for pati ents with stage IV 
melanoma. The response rate to dacarbazine in most studies is 10 -15%, primarily partial responses 
that tend to be of short (2 -3 months) duration. Few durable complete responses are seen after 
treatment with dacarbazine. A meta -analysis o f 74 studies published between 1974- 1995 reviewed 
the ineffectiveness of dacarbazine- based chemotherapy as the median survival of enrolled patients 
was 8.8 months  (8). Addition of other cytotoxic agents to dacarbazine adds little clinical benefit 
and incre ases toxici ty (9).   
1.3 Cytokines for Melanoma 
 I
nterleukin -2 received FDA approval in 1998 as treatment for metastatic melanoma despite 
concerns about toxicities and poor tolerability. In a series of single arm clinical trials (n=270 
patients), the response rate to high dose Interleukin- 2 is 16% (6% complete response rate) . As 
reported, ten of the 16 patients who achieved a complete response remain disease free at a median follow up of 5 years  (10). Six deaths occurred due to toxicity. This published experience using high 
dose IL -2 suggests that immunomodulation has a role in the treatment of this disease and in fact, 
may be curative in a small group of patients.  
1.4 Vaccines for Melanoma 
S
ince 1970, investigators have pursued the hypothesis that melanoma is inherently immunogenic 
and elicits an immune response that can be, in some instances, protective (11).  As a result, 
therapeutic immunization strategies have evolved over the pas t decade to develop more 
contemporary approaches based on molecular techniques of antigen identification and immune monitoring.  As one example, the molecular cloning of several melanocyte- lineage antigens (MLA)  
DC Vaccine for Melan oma Page 7 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. has prompted investigators to identify and i solate immunogenic peptides that can be used in 
vaccination protocols  (13). These candidate melanoma tumor antigens include: gp100/pMe117, 
MART -I, Melan -A, tyrosinase as well as antigens from the cance r-testis family (MAGE family) 
which are known to be  expressed only in testis and placenta in normal tissues  (14, 15) . In normal 
adult t issues, each MLA is expressed at low levels with expression restricted to melanocytes and 
retina pigmented epithelium  (16).  
1.4.1 Gp100 Melanoma A ntigen V accines  
T
he gp100 antigen has been  studied in detail. Three candidate peptides  (G154, G209- 2M and G280-
9V) that bind HLA -A2 (the most common class I allele expressed by ~50% of the population) have 
been identified and each is known to be immunogenic in patients with melanoma  (14)). One peptid e 
named (G209- 2M (also called gp100:209- 217) has been studied extensively and shown to be 
immunogenic when given subcutaneously with adjuvant  (17).  In our work, the (G280- 9V (also 
called gp100:280- 288) peptide was given with autologous dendritic cells (without IL -2 or any other 
cytokine) and shown to be immunogenic in patients with advanced melanoma  (18). The third 
peptide epitope named G154 has also been studied in some detail  (19). Other gp100 related peptides 
that are restricted to HLA -A3 are known but are less well studied  (20).   
1.4.2 Melanoma Neoantigens 
A
mong cancer genomes, cutaneous melanoma harbors the largest number of non -
synonymous mutations. Ultraviolet light exposure is a major risk factor for cutaneous 
melanoma and whole genome sequencing reveals the high rate of UV light  induced 
mutational alterations  (21). We have hypothesized that UV light induced non-synonymous 
mutations generate patient- specific neo antigens which could be targeted by vaccination to 
elicit melanoma -specific T cells. Based on our published report  to identify tumor -specific 
neoantigens from melanoma patients samples, we have been able to identify >20 candidate peptide neoantigens restricted to the HLA -A*0201 allele  with ~50% promoting an immune 
response upon incorporation into a vaccine  (22). Thus, inclusion of candidate patient -
specific neoantigen peptides alone or in combination with the gp100 melanoma shared 
peptides into a vaccine  is predicted to improve the breadth of the immune response directed 
against the tumor.  
1.5 Dendritic Cells 
D
endritic cells (DC) serve a critical role in capturing and presenting antigen in the initiation of 
immunity against infectious pathogens and cancer . A variety of technical advances involv ing the 
isolation of human DC as well as an improved understanding of DC biology hav e led investigators 
to propose using autologous DC as adjuvant for peptide vaccination in cancer, including melanoma  
(23). The initial clinical reports  conclude that DC immunization is safe and well tolerated; serious 
adverse events related to DC vaccination are rare (24). Interestingly, clinical responses have been 
documented by numerous investigators in a variety of malignancies including melanoma (18,25).  
DC Vaccine for Melan oma Page 8 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 1.6 Regulatory T Cells 
R
ecent advances in immunology confirm the presence of a small populat ion of circulating 
CD4+CD25+ T cells (known as regulatory T cells or Treg) that function to suppress T cell 
immunity toward pathogens and cancer. In healthy adults, approximately 5% of peripheral blood 
CD4+ T cells are Treg based on co -expression of CD25 and the transcription factor FoxP3 (26). 
Depletion of Treg by administration of low dose cyclophosphamide is sufficient to allow tumor  
rejection after peptide vaccination in model systems. This strategy was attempted clinically in the 
1980’s using cyclophosphamide together with a f irst generation (whole cell, irradiated) vaccine and 
shown to be safe and well tolerated . Several randomized  trials later confirmed that vaccine given 
with cyclophosphamide is more immunogenic  (27).  Currently, the use of low dose 
cyclophosphamide which can be given either b y infusion or orally is an  effective strategy to 
eliminate Treg in patients prior to vaccination and is currently being evaluated at multiple centers. 
1.7 Study Rationale 
C
ancer  vaccines represent a promising area of clinical investigation in solid tumors based on 
evidence of clinical activity and minimal toxicity  (28). Recent progress in immuno -oncology 
supports continued clinical evaluation of cancer vaccines in melanoma patients especially in 
combination with checkpoint inhibitors  (29) . The central hypothesis is that checkpoint inhibition 
will permit vaccine -elicited T cells to expand and traffic to the tumor microenvironment for more 
efficient elimination of the cancer cells.   
The primary endpoint is immunological response based on tetramer assays performed on 
longitudinal blood samples obtained at multiple time points . Immunological response is based on 
measuring increased numbers of antigen peptide -specific CD8+ T cells as measured by the tetramer 
assay.  In the proposed study, the tetrame r assay will be performed at the designated time points . 
The additional laboratory correlative assays such as the 51Cr release assay and functional assays 
will be performed after the third dose. The primary endpoint will also include evaluating the safety 
and tolerability of the mature dendritic cell vaccine.  Secondary study endpoints are described in 
Section 2.2.  
We propose to obtain tumor tissue to evaluate various biomarkers including the expression of PD -
L1 antigens and characterize the tumor infiltrating lymphocytes, and perform exploratory studies 
to discover markers of resistance using tumor biopsy specimens collected at the indicated time 
points. These correlative laboratory studies are viewed as a high priority that will allow scientists 
to better understand the mechanisms of response/resistance to therapy.  
1.8 Investigational Product Update: September 2016 
S
ince the IND was open , we have published two reports documenting the safety, tolerability, and 
immunogenicity of the vaccine. Our initial publication reported the initial cohort of patients that 
received the mature DC  (mDC)  vaccine with the three gp100 peptides restricted to HLA -A*02:01. 
Maturation of D C was performed by activation of cells with CD40 -ligand (CD40L) and Interferon-
γ (IFN -γ). Of the seven patients treated, six developed sustained T cell immunity to all 3 melanoma 
peptides (30) . Importantly, 3 patients developed a confirmed clinical response by RECIST criteria. 
DC vaccine derived IL -12p70 levels positively correlated with time to progression ( TTP) as did 
type-1 immunity as assessed by IFN -γ/IL-13 ratios. A pathway specific defect in IL -12p35 
transcription was identified in clinical non -responder patients and gp100 specific T cells were type -
2 polarized. Incorporation of TLR3 (poly I:C)  and TLR8 (R848) agonists into the CD40L/IFN - γ 
DC Vaccine for Melan oma Page 9 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. activation protocol for DC maturation corrected the IL -12p70 production defect. 
T
he second published report involved the incorporation of neoantigen peptides together with 2 
gp100 peptides using autologous DC matured with CD40L/IFN -γ/TLR3/TLR8 agonists  (refer to as 
mDC3/8) (22). Our group employed next generation sequencing methods with a novel 
bioinformatics pipeline  to identify missense mutations in surgically resected melanoma metastases 
from patients with advanced disease that previously received ipilimumab. The DC vaccine led to 
an increase in  the frequency of  naturally occurring neoantigen- specific immunity and revealed 
previously undetected HLA class I restricted neoantigens in patients. Vaccination promoted a 
diverse neoantigen -specific T cell receptor repertoire and most importantly, was safe and well 
tolerated.  Please refer to the Investigator Brochure for current toxicity information.   
We 
have treated two additional patients since this publication using the same vaccine protocol. One 
patient (MEL66) had progression after ipilimumab followed by dabr afenib/trametinib combination 
and the residual disease was surgically resected. She received the vaccine as adjuvant therapy, 
tolerated the treatment well with no adverse events and remains alive with no measurable disease 18 months later. The other patient (MEL69) had widely metastatic relaps ed/refractory disease at 
the start of the vaccine protocol. He received two vaccine doses without side effect or toxicity but 
had documented disease progression and was removed from the study. He died a few weeks later 
due to disease progression.  
We h
ave received funding from NCI and the Parker Institute for Cancer Immunotherapy   to accrue 
additional patients for enrollment into the vaccine protocol. The hypothesis to be tested is that anti -
PD-1 therapy inhibits adaptive immune resistance by enhancing neoantigen -specific T cell 
immunity within the tumor microenvironment leading to more effective tumor regression.  
1.9 Major Study Update: November 2017 
The results of the BMS 238 clinical trial evaluating nivolumab versus ipilimumab as adjuvant 
therapy for surgically resected stage 3/4 melanoma have been published ( 31). FDA  has accepted 
for priority review its supplemental Biologics License Application for  nivolumab to treat patients 
with melanoma in the adjuvant setting and FDA approval is anticipated.   Based on this publication, 
the study has been further amended to allow for subjects without measurable disease (i.e. disease 
that has been completely resected) to enroll on this study.   
2.0 OBJECTIVES  
2.1 Primary Objective 
1.T
o determine the immunological res ponse based on measuring increased numbers of peptide
specific T cells as calculated by the tetramer assay.
2.T
o assess the safety and tolerability of the mature dendritic cell vaccine (mDC3/8  vaccines ).
2.2 Secondary Objectives  
1.T
o determine the clinical response rate using RECIST 1.1 criteri a
2.T
o determine the time to progression
DC Vaccine for Melan oma Page 10 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 3.T
o assess regulatory T cell depletion after cyclophosphamide administratio n.
4.T
o perform exploratory biomarker analysis of accessible tumors
5.T
o determine the safety and side effect profile of the dendritic cell vaccine (mDC 3/8 vaccines )
administered to patients given  after a single dose of cyclophosphamide .
3.0 ELIGIBILITY CRITERIA  
P
atients must fulfill the following eligibility requirements:  
3.1 Inclusion Criteria 
1.Histologically confirmed s tage III and stage IV M1a/M1b/M1c melanoma.  Measurable disease 
is not required for eligibility and patients with completely resected disease are permitted .
2.Male or f emale patients age ≥  18 years
3.E
COG performance status 0 -2
4.R
equired initial laboratory values (performed  within 14 days prior to  eligibility  confirmation
by physician- investigator ):
a.WBC >3  THO/µL
b.Hg ≥ 9.0 g/dL
c.Platelets >75  THO/µL
d.Total  Bilirubin < 2.0 mg/dl ; unless the subject has known or suspected Gilbert syndrome
for which ≤ 3 mg/dl is permitted
e.Serum Creatinine < 2.0 mg/dl
5.S
ubjects of reproductive  potential must agree to use a medically accepted  birth control method
during the trial and for at least two months following the trial.  Please see Section 5.0 for
a
dditional details .
6. P
rovide written informed consent.
3.2 Exclusion Criteria 
1.P
rior treatment with more than one line of cytotoxic chemotherapy ; prior treatment with one
line of cytotoxic chemotherapy is permitted .  Prior treatment with targeted therapy (such as
ipilimumab , anti- PD-1, or BRAF + MEK inhibitor  combination ) is permitted.
2.A
ctive untreated CNS metastasi s
3.A
ctive infection
4. P
rior malignancy (except non- melanoma skin cancer) within 3 years
DC Vaccine for Melan oma Page 11 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 5. Pregnant or nursing (lactating) women
6.C
oncurrent treatment with high-dose systemic corticosteroids ; local (inhaled or topical)
steroids are permitted
7. K n
own allergy to eggs
8. P r
ior history of uveitis or autoimmune inflammatory eye disease
9. K
nown positiv ity for hepatitis BsAg, hepatitis C antibody, or HIV antibody
4.0 REGISTRATION  
A
t the time a subject consents to participate in this study, the subject should be registered in the PennCTMS 
(i.e. Velos) . Once subject eligibility has been confirmed by a physician- investigator, apheresis collection 
and the manufacturing of the study vaccine may commence. Patients who fail apheresis or who do not 
receive vaccine due to other reasons will be replaced and will not be considered evaluable.  
Each
 Subject is identified in the study by a Subject Number that is assigned when the subject is first 
consented and is retained as the primary identifier for the subject throughout his/her entire participation in 
the trial. T he Subject Number consists of the Protocol Number with a sequential subject number suffixed 
to it, so that each subject is numbered uniquely across the entire database.  Once assigned, the Subject Number must not be reused for any other subject and the Subject Number for that individual must not be 
changed, even if the subject is re- screened. If the subject fails screening for any reason, the reason will be 
entered into the End of Study eCRF. 
5.0 PATIENT RECRUITMENT AND SCREENING  
A
pproximately 12 evaluable subjects will be enrolled in this study.  Patients who fail apheresis or who do 
not receive vaccine due to other reasons will not be considered evaluable and will be replaced. 
P
atient s will be identified through the clinical practices of the  invest igator or su b-invest igators and through 
refer rals from outside hospitals and physicians.  The study will be posted on clinicaltrials.gov, and 
publicized via University of Pennsylvania or Abramson Cancer Center press releases. No  direct-to-
patient adve rtising will be perform ed. 
Fem
ale patients  of reproducti ve potential  (women who have re ached menarc he or wom en who ha ve not  
been post- menopa usal for at least 24 c onsecutive mon ths, i.e., who have had mens es with in the preceding 
24 months, or ha ve not undergone a sterilization proce dure [hy sterectomy or bila teral oophorec tomy]) 
must  have negative p regnancy test perfo rmed at the time of screening and within 30 days of the subject’s 
1st DC vaccine (Day 1). 
P
atie
nts must  agree not to particip ate in a conception proce ss while participating in this study (e.g., active 
attempt to become pregnant or to impre gnate, sp erm donation, in vitro fertilization). Addit ionally, if 
particip ating in sexual activity that could lead to pregnancy, the study patient  must ag ree to use at least 
one reliable method of contraception du ring th eir participation in the study.  
DC Vaccine for Melan oma Page 12 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. Acceptable bi rth control includ es one  of the  following methods: 
•Total abstinence (no sexual relations)
•Female sterilization - surgical removal of both ovaries (woman's reproductive system that store s
a
nd releases eggs for fertilization and produces female sex hormones), or tubal ligation (having
your “tubes tied”) at least six weeks prior to signing this con sent.
•Mal
e sterilization (i.e. vasectomy)
•Condoms (male or female) with or without a  spermic idal agent
•Diaphragm or cervical cap with spe rmicide
•Intra uterine de vice (IUD)
•Hormonal-based c ontraception
P
atient s who are not  of repr oductive pote ntial (wom en who have been post-menopa usal for at least 24 
consec utive months or ha ve undergone hy sterectomy, sa lpingectomy,  and/or bilatera l oopho rectomy or 
men who ha ve doc ument ed azoospermia) do not require  the use of c ontraception.  Ac ceptable 
documentati on of sterilization, azoospe rmia, and meno pause is spec ified below:  
Wr
itten documentation by cli nician or clinician’s staff through one of the followin g: 
1.Physician re port/letter
2.Operative report or other source documentation in the patient record (a la boratory report of
azoospe rmia is required to docume nt su ccessful v asectomy)
3.Discharge summ ary of sterilization procedure or hysterectomy, and/or salpingectomy ,
ooph
orectomy
4. Laboratory report of azoospermia
5.Follicle stimulating hormone measurement elevated into the menopausal range
6.0 CONCOMITANT THERAPY  
A
ll prescription and nonprescription medication, vitamins, herbal and nutritional supplements, taken by the 
patient within 14 days prior to eligibility confirmation by a physician- investigator will be recorded.   
Concomitant medications will continue to be collected at every visit thereafter, until the subject has 
discontinued participation in the study. Any additions, deletions, or changes of these medications will be 
documented.  
F
or all subjects, a 2 8-day washout period for any prior therapy (including adjuvant interferon) is required 
prior to the first vaccine dose.   This does not include adjunctive therapies (i.e. steroids, growth factors, etc); 
just prior therapies for their melanoma.  
H
igh-dose systemic corticosteroids (i.e., prednisone >10 mg daily or equivalent) are prohibited.  
Low-dose s ystemic corticosteroids (i.e. prednisone ≤10 mg daily or equivalent) are permitted , as well as 
local steroid s (inhaled or topical) . 
DC Vaccine for Melan oma Page 13 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 7.0 INVESTIGATIONAL PRODUCTS 
7.1  Dendritic Cell Vaccines (mDC3/8 vaccines with and without influenza ) 
7.1.1 Agent Description  
F
or this study, Dendritic Cell Vaccines (mDC3/8  vaccines) are named as follows:  
•Priming Vaccine – hereafter identified as DC Vaccine #1
•Booster Vaccines– hereafter identified as DC Vaccine #2  and DC Vaccine #3
A
utologous dendritic cells pulsed with 12 (or fewer) melanoma tumor -specific peptides.  
For DC Vaccine #1  only, inactivated influenza vaccine is added to the DC preparation to 
provide a source of class II antigen to induce CD4+ helper T cells. For patients who are 
not HLA -A2 positive, the gp100 peptides are omitted since they will not bind.  Total 
number of peptides used will remain at a maximum of 12. 
P
lease refer to the Investigator’s Brochure for additional information. 
7.1.2 Mechanism of Action   
I
nduction of antigen- specific CD8+ T cells that function to promote tumor regression 
through multiple mechanisms including 1) direct tumor cytolysis requiring cell to cell 
contact; 2) secretion of cytokines such as Interferon- γ and t umor necrosis factor. 
Administration of cyclophosphamide 3-4 days prior to the first immunization will deplete 
regulatory T cells that serve to inhibit the generation of immunity. Multiple immunizations are necessary to elicit and sustain CD8+ T cell immunity.  
7.1.3 Pharmacodynamics/ Kinetics  
I
mmunological monitoring is planned to assess the response to DC immunization. 
Regulatory T cell (Treg) counts will be assessed pre- treatment.  
7.1.4 Formulation 
S
ynthetic peptides (> 98% purity) will be obtained commercially.   
7.1.5 Availability  
C
ells used to manufacture the DC vaccines w ill be obtained by apheresis prior to 
administration of cyclophosphamide .  
7.1.6 Preparation 
T
he manufacture and release testing of the vaccine product will be performed by the 
Clinical Cell and Vaccine Production (CVPF) at the University of Pennsylvania. The 
vaccine product will be manufactured from the patients’ apheresis product. The vaccine 
products are not released from the CVPF until release criteria are met.  
V
accine will be made starting from fresh peripheral blood mononuclear c ells (PBMC)  in 
DC Vaccine for Melan oma Page 14 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. accordance with the Investigator’s Brochure. DC preparations that fail to pass each release 
criteria will be held and not released for patient administration.  
7.1.7 Packaging and Labeling 
T
he investigational product will be  release d at room temperature in an infusion bag and  
affixed with a label containing information regarding the dose, the number of cells and 
volume and the following statements “FOR AUTOLOGOUS USE ONLY” and “Caution: 
New Drug -Limited by Federal Law to Investigational Use”.  In addition , the label will have 
at least two unique identifiers.  
7.1.8 Administration  
D
endritic cells (mDC3/8 Vaccine) will be administered i ntravenously at the following 
doses: 
•DC Vaccine #1 ( Priming Vacc ine Dose ):  maximum of 7.5- 15 million DC per
peptide
•DC Vaccine #2 and #3 ( Booster Vaccine Doses ): maximum of 1- 5 million DC per
peptide x 2 doses administered ~ q6 weeks apart.
Pl
ease see Section 8 .4 for additional details.  
7.1.9 Potential Toxicities  
P
lease refer to the Investigator ’s Brochure for toxicity information.  
7.1.10 Return or Destruction of Study Drug  
The
 investigational product may need to be returned to the manufacturing facility for a 
variety of reasons, including but not limited to: 1) Mislabeled product; 2) Condition of 
patient prohibits infusion/injection, and 3) Subject refuses infusion. Any unused product will be re turned to CVPF for freezing by CVPF personnel.  Final disposition of the 
investigational product must be documented appropriately.  
7.2 Cyclophosphamide 
7.2.1 Agent Description  
 
Cyclophosphamide is an FDA -approved chemotherapeutic agent. Cyclophosphamide is 
consi dered an investigational agent on this protocol since it is not the standard of care in 
this patient population and is not being used in accordance with its approved labeling. However , while administered for research purposes as part of this study, it will be prepared 
and infused in accordance with its approv ed package insert . Full details on its mechanisms 
of action and toxicity profiles can be found in the approved package insert . 
DC Vaccine for Melan oma Page 15 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 7.2.2 Receipt and Storage 
C
ommercial cyclophosphamide will be obtained through the site- designated research 
pharmacy for research purposes.  It will be stored according to the manufacturing 
instructions in the approved package insert. 
7.2.3 Premedication  
A
ll patients receiving cyclophosphamide may  be premedicated with an anti -emetic.  The 
choice of premedication will be left to discretion of the treating physician.   
Cyclophosphamide is associated with moderate to high emetic potential, and antiemetics 
are recommended to prevent nausea and vomiting. Combining NK1R antagonist (e.g. 
aprepitant or fosaprepitant) with 5- HT3 receptor antagonist (e.g. ondansetron) is 
recommended, but may be modified per investigator discretion and institutional standards. 
Glucocor ticoids (e.g. dexamethasone) should be avoided as these agents may affect vaccine 
efficacy . 
7.2.4
 Admin istration  
A
 single dose of 300 mg/m2 cyclophosphamide will be administered  via intravenous 
infusion  on Day -3 (+/ - 1 day) prior to the first dendritic cell v accine (mDC3/8).   
7.2.5
 Potential Toxicities  
P
lease refer to the cyclophosphamide package insert for toxicity information.  The package 
insert describes the risks of cyclophosphamide when given as part of routine care.  We 
expect similar side effects when administered as part of this study.  
7.3 Anti-PD-1 (Pembrolizumab) 
P
embrolizumab is FDA approved for the treatment of metastatic melanoma.  Beginning as early as 
14 days after the subjects’ last DC Vaccine, subjects will commence treatment with pembrolizumab 
(anti-PD-1 therapy)  as per standard of care.  The timing of pembrolizumab administration will be 
at the discretion of the physician investigator . Treatment  will be administered per the FDA 
approved package insert .  As administration and duration of treatment will be driven by routine 
care and not per protocol requirements, these drugs will not be supplied by the study and will be 
obtained commercially through the subjects’ insurance provider.  Please refer  to the pembrolizumab 
package insert for toxicity information.  
8.0 STUDY PROCEDURES  
8.1 On-study Biopsies 
O
nstudy biopsies wi ll be performed  as follows: 
•Post DC Vaccine Biopsy #1: Will occur after the subject’s last  DC vaccine, and prior to
initiation of treatment with Anti- PD-1 therapy .
•P
ost DC Vaccine Biopsy #2: 4 weeks (+/ - 5 days) after the subject’s first dose of Anti -PD-
1 therapy .
DC Vaccine for Melan oma Page 16 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. •Post DC Vaccine Biopsy #3: 8 weeks (+/- 1 week) after the subject’s first dose of Anti -
PD-1 therapy .
O
nstudy biopsies will only be performed in patients with accessible lesions.  This will be 
determined by the treating investigator.   
8.2 Dendritic Cell (mDC3/8) Preparation 
A
fter eligibility has been confirmed by a physician -investigator , subjects will undergo a large 
volume apheresis procedure  (approximately 15 -20 L volume) at the HUP Apheresis Unit according  
to standard procedures for autologous transplantation, to allow for a target of 1.5- 2.0 x 1010 
mononuclear cells  to be collected . The actual volume apheresis procedure to be performed will be 
at the discretion of the physician -investigator in consultation  with transfusion medicine. The 
apheresis product will be transported to the CVPF manufacturing facility  and manufactured in 
accordance with the current mDC3/8 Investigator’s Brochure.  
If the initial apheresis collection does not yield an adequate number of cells required for 
manufacturing all required DC Vaccines, the second study apheresis  procedure (typically 
performed after the last DC Vaccine and prior to administration of Anti -PD-1 therapy) may be 
moved up to an earlier study timepoint to allow for required manufacturing. An approximate 
15 liter volume procedure will be performed, and the product processed as indicated  in the 
Investigator’s Brochure.   
C
ells remaining after manufacturing is complete may be banked for research purposes. 
8.3 Treg Depletion 
P
atients will return  to the Hospital of the University of Pennsylvania to receive a single dose of IV 
Cyclophosphamide ( 300 mg/m2)  on Day -3 (+/- 1 day)  prior to DC#1 dose , in order  to deplete 
circulating Treg prior to Dose #1. Patients may receive premedication at the discretion of the 
treating physician. Only a single dose of cyclophosphamide is given to each patient  during the  
initial  treatment phase prior to DC vaccine #l.    
8.4 Adm inistration of Dendritic Cell Vaccines (mDC3/8 vaccines with and 
without influenza) 
A total of 3 DC vaccines will be administered, approximately 6 weeks apart  (+/- 2 weeks) beginning 
on Day 1. The timing of the DC Vaccine Infusions will be calculated from the 1st DC Vaccine 
Infusion (i.e. Day 1, also known as Week 1). Thus, the 2nd DC Vaccine Infusion is planned for 6 
full weeks after Day 1/Week 1 at ~Day 43 (i.e. the end of Week 6 and the beginning of Week 7). 
Similarly, the 3rd DC Vaccine Infusion is planned for 12 full weeks after Day 1/Week 1 at ~Day 85 
(i.e. the end of Week 12 and the beginning of Week 13).  V accines cannot be administered until all 
toxicities  > grade 2 have resolved to baseline.   
A
ll infusions will take place at the Hospital of the University of Pennsylvania by a licensed 
Registered Nurse. Each DC vaccine is administered by intravenous infusion through either a 
peripheral venous line or a central venous line.  A macrodrip intravenous tubing will be used to 
infuse DC vaccine  by gravity (i.e. no infusion pump will be used ), therefore each infusion will take 
less than 15 minutes .  All subjects will have vital signs  (including temperature, respiration rate, 
pulse, blood pressure, oxygen saturation)  assessed prior to each infusion.  After the first infusion, 
DC Vaccine for Melan oma Page 17 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. subjects will be observed for 2 hours  after the end of the infusion, with vital signs assessed  every 
30 minutes (+/- 5 minutes) from the start of the infusion.  After each subsequent infusion, subjects 
will be observed for 30 minutes after the end of the infusion, with vital signs assessed every 30 
minutes (+/- 5 minutes) from the start of the infusion. If subjects develop temperature greater than 
38ºC , acetaminophen 650mg PO should be given and the PI notified the same day. After the 
required observation period  is complete, subjects may be discharged to home from the treatment 
area.  
Administration of the DC Vaccine may be delayed for a number of reasons, including toxicity, 
investigator discretion, etc. T reatment delays o f up to 21 days will be allowed. If administration of 
the next planned dose is delayed greater than 21 days, the patient will discontinue the study vaccine and will not be eligible to receive additional trea tment on this protocol. Treatment delays should 
be to be kept to a minimum and every effort is to be made to maintain a planned schedule.  
8.5 Immune Monitoring 
S
tarting on D ay 1/Week 1  (DC vaccine #1) and weekly thereafter through Week  18 (~Day 120), 
up to four 10mL green top tubes (BD vacutainer sodium heparin tube,  ~ 40 mL ) will be  obtained 
by venipuncture for immune monitoring  analysis. After  the Week 18 collection , the frequency of  
peripheral blood draws will shift to q3 weeks for up to 12 additional weeks (i.e. at Week 21, Week 
24, Week 27, and Week 30) . Sample collection will continue on this schedule, regardless of the 
timing of the 2nd and 3rd DC Vaccinations  and any subsequent Anti -PD-L1 therapy .  Any missed 
sample collections must be documented appropriately.  These blood samples will be used for 
tetramer assay and determination of Treg cell counts. The blood samples will be transported to the 
Dr. Carreno’s  laboratory (SPE 8 -309, bays 305B-307B).  
P
atients will also undergo two additional  apheresis procedure s to collect lymphocytes for functional 
laboratory assays, to determine immunity against the melanoma peptides, at the following 
timepoints :  
•Apheresis # 2:  Collected after the subject’s last DC Vaccine and prior to anti -PD-1 therapy
being administered.  Note: As per Section 8.2 above, this Apheresis Collection may b e
m
oved up to an earlier study timepoint if deemed necessary for manufacturing purposes .
•A
pheresis #3 (Optional) : Approximately 4- 8 weeks after initiation of anti- PD-1 therapy
(Optional) .
T
he additional apheresis procedures #2 and #3 noted above will be performed at the HUP Apheresis 
Unit according to standard procedures . At each  timepoint, an approximate 15 liter volume apheresis  
procedure will be performed.  These cells  will then be transported to Dr. Carreno’s laboratory for 
processing.   
Please refer to the Study Calendar in Section 10.0 for additional information related to study 
timepoints.  
8.6 Assessment of Clinical Response 
P
atients will undergo routine clinical monitoring, blood work and  physical examination s. RECIST 
1.1 criteria [56] wil l be used for tumor response assessment after the subject’s last vaccine dose. 
CT of the chest, abdomen, and pelvis is the preferred imaging modality for assessment. In certain instances, MRI scan s or other imaging modalities may be performed at physician- investigator 
discretion . For cutaneous lesions, direct measurement is also acceptable and visible lesions should 
DC Vaccine for Melan oma Page 18 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. be photographed.  After initiation of Anti -PD-1 therapy, subjects will be assessed for clinical 
response according to routine care gu idelines. Data from any response evaluations performed while 
the subject remains onstudy will be collected for research purposes. 
P
lease refer to the Study Calendar in Section  10.0 for complete details.  
8.7 Anti-PD-1 Administration 
B
eginning as early as 14 days after the subjects’ last DC Vaccine, subjects will commence treatment 
with pembrolizumab (anti-PD-1 therapy) as per standard of care.   The timing of pembrolizumab 
administration will be at the discretion of the physician investigator.  Treatment with 
pembrolizumab will be administered per the FDA approved package insert and will not be driven 
by protocol requirements.   
D
uring anti -PD-1 administration subjects will continue to have blood samples collected for immune 
monitoring purposes  in accordance with Section 8.5 , and will undergo apheresis and biopsy 
procedures for research purposes as outlined above.  
I
f a subject dose not receive pembrolizumab per routine care post -DC Vaccine, either at the 
physician- investigator’s discretion or per subject decision, the subject will complete their End of 
Study Treatment Visit as scheduled and continue to have their immune monitoring samples 
collected per protocol.  However , the subject would not undergo the Post -Anti-PD-1 Therapy Visit 
#1 or Visit #2.  The subject would then complete the End of Study visit once immune monitoring 
sample collection is completed per protocol requirements.  
9.0 POTENTIAL TOXICITY AND DOSE MODIFICATIONS  
Any toxicities of grade 2 or higher , regardless of attribution/expectedness , should be reported immediately 
to the Principal Investigator .  Additional vaccines cannot be administered until all toxicities  > grade 2 have 
resolved to baseline.  
9.1 Dose Limiting Toxicity 
Is
 defined as  any of the  below events determined to be at least possibly related to the dendritic cell 
vaccines (mDC3/8  vaccine ): 
•Any Grade 3 or greater hematological and non hematological toxicities
•Any Grade 3 or greater allergic reaction
•Any Grade 3 or greater autoimmunity that involves vital organ (heart, kidneys, brain,
eye, liver, colon and adrenal gland).
I
f a subject experiences a DLT, they will be discontinued fro m additional study treatment.  
Subjects discontinued from study treatment due to a DLT will continue to be followed per the 
Study Calendar in Section 10.0 until the End of Study visit , and for adverse events per Section 
13.1.  Dose -limited toxicities will be  confirmed by the Sponsor Medical Director.  The Medical 
Director  will also assess the impact of dose- limiting toxicities on subsequent enrollment/ 
treatment activity.  In the event of a DLT and treatment discontinuation, immune monitoring 
blood samples will continue to be collected until the EOS visit. Please refer to  Section  13.7 for 
study stopping rules.   
DC Vaccine for Melanoma 
Protocol Version 9.08-10-2021 
10.0 STUDY CALENDAR 
Tests and 
Observations 
Signed infonned consent 
Tumor Biopsy" 
Medical Histo1y 
Physical Examination 
ECOG Perfonnance 
Status 
Vital Sign Assessment" 
Apheresis 
Cyclophosphamide 
Dendritic Cell 
V a.ccination 
Routine Anti-PD-1 
Thera.ov 
Tumor measurements' 
CBC, CMP1, LDH 
PTIPTT 
Immune monitoringv 
Pregnancy test Screening/ 
Enl"Ollment,.. 
X Pre-
Treatment 
(� 14 days 
prior to 1st 
DC 
Vacciner 
X------------------------- X 
X X 
X X 
X X 
Xb
xg Xh
XU X 
X X 
Xd 
xe xe Cyclo-
phosphamide 
Day -3 (+/-1 
day) 
xi Page 19 of 38 
DC Vaccination Visits (Every 6 Post-DC Vaccine Follow-up weeks +I-2 weeks)" 
End of Study 
Treatment Visit Post Anti-PD- Post Anti-PD- End of DC DC DC (~10-28 1 Therapy-1 Therapy-Study Vaccine Vaccine Vaccine Days.After Last Visit #1 Visit #2 VisitP #1 #2 #3 DC Vaccine and ( 4 weeks after (8 weeks afte1· (~Week30 (Priming (Booster (Booster P1ior to initiation of initiation of Post-DC Vaccine) Vaccine) Vaccine) Initiation of Anti-PD-I Anti-PD-I Vaccine 
Anti-PD-I Therapy +/-5 Therapy +/-1 #1) 
Day 1 ~Day43 ~Day 85 Therapy)s days)t week)t 
(Week 1) (+/-14d) (+/-14d) 
X4 X X 
X X X X 
X X X X 
XkXkXkX 
Xb,c xr
X'1 xn xn 
xo -------------------------------------------- ---------------------xo
X xm ________________________________________ X 
X X X 
X:! Xd Q3 weeksd XP 
AE assessment i X ------------------------------------------------------------------------------------------------------------------------------------ Xi 
Concomitant Medications X X -------------------------------------------------------------------------------------------------------------------------------------- X 
CONFIDENTIAL 
This protocol is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor. 
DC Vaccine for Melanoma 
Protocol Version 9.08-10-2021 Page 20 of38 
DC Vaccination Visits (Every 6 Post-DC Vaccine Follow-up weeks +I-2 weeks)" 
End of Study 
Pre- Treatment Visit Post Anti-PD- Post Anti-PD-
Treatment Cyclo-DC DC DC (~10-28 1 Therapy- 1 Therapy-
Tests and Screening/ (� 14 days phosphamide Vaccine Vaccine Vaccine Days.After Last Visit #1 Visit #2 
Observations Enl"Ollment,.. 
prior to 1st Day -3 (+I-1 #1 
(Priming #2 #3 DC Vaccine and ( 4 weeks after (8 weeks afte1· (Booster (Booster 
Survival DC day) P1ior to initiation of initiation of 
Vacciner Vaccine) Vaccine) Vaccine) Initiation of Anti-PD-I Anti-PD-I 
Anti-PD-I Therapy +/-5 Therapy+/- 1 
Dayl ~Day43 ~Day 85 Therapy)s days)t week)t 
(Week 1) (+/-14d) (+/-14d) 
a.Please refer to Section 8.1 for additional details. Perfonned in patients with accessible lesions as determined by the treating investigator.
b. To obtain mononuclear cells for DC generation. Apheresis #1 will be performed with an approximate volume collection of 15-20 liters ~7 days prior to the
first DC vaccine. If the initial apheresis collection does not yield an adequate number of cells required for manufacturing all required DC Vaccines, the
second study apheresis procedure (typically perfonned after the last DC Vaccine and prior to adrninistration of Anti-PD-1 therapy) may be moved up to an
earlier study timepoint to allow for required manufacturing. An approximate 15 liter volume procedure will be performed, and the product processed as
indicated in the Investigator's Brochure.
c.To obtain mononuclear cells for illllllune monitoring. Apheresis #2 will be performed after DC vaccine #3 and prior to adrninistration of anti-PD-1 therapy at
the End of Study Treatment Visit. Please refer to Section 8.5 for additional details.
d.Immune monitoring studies will be drawn in l0mL green top tubes (BD vacutainer tube). At screening, up to four l0mL green top tubes will be collected.
Starting on Week 1/Day 1 (DC vaccine # 1) and weekly thereafter through Week 18 ( ~Day 120), up to four 1 0mL green top tubes ( ~40 mL total) will be
drawn for immune monitoring analysis. After the Week 18 collection, the frequency of peripheral blood draws will shift to q3 weeks for up to 12 additional
weeks (i.e. at Week 21, Week 24, Week 27, and Week 30). Sample collection will continue on this schedule, regardless of the tirning of the 2nd and 3rd DC
Vaccinations and any subsequent Anti-PD-1 Therapy. Any missed sample collections must be documented appropriately. Please see Section 8.5 for
additional details.
e.Females of childbearing potential. A serum or urine pregnancy test will be accepted. A pregnancy test must be performed within 30 days prior to DC Vaccine
#1 (Day 1).
f.Apheresis #3 ( optional) will be performed ~ 4-8 weeks after initiation of anti-PD-1 therapy. Please refer to Section 8.5 for additional details.
g.Must be completed within 28 days prior to physician-investigator confirmation of eligibility.
h. CT scans do not have to be repeated at pre-treatment as long as screening CT scans were within 28 days of the 1st DC vaccine.
1. Please see Sections 7.2 and 8.3 for additional details.
j.Collection of AEs will begin at the time of the first apheresis procedure (Apheresis # 1) and continue until subject discontinuation or the End of Study Visit.
Please refer to Section 13.1 for additional information.
CONFIDENTIAL 
This protocol is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor. End of 
Study 
VisitP 
(~Week30
Post-DC 
Vaccine 
#1) 
X 
DC Vaccine for Melan oma Page 21 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. k.Vital sign assessments include  t emperature, respiration rate, pulse, blood pressure, and oxygen saturation.  Vital signs will be assessed prior to each infusion.
1st DC Vaccine Infusion: S ubjects will be observed for 2 hours after the end of the infusion, with vital signs assessed every 30 minutes (+/ - 5 minutes) fro m
t
he start of the infusion. S ubsequent DC Vaccine Infusions: S ubjects will be observed for 30 minutes after the end of the infusion, with vital signs assesse d
ev
ery 30 minutes (+/ - 5 minutes) from the start of the infusion.
l.Comprehensive metabolic panel including Glucose, BUN, Creatinine, Sodiu m, Potassium, Calcium, Total Protein, Albumin, Total Bilirubin, Alkaline
phosphatase, ALT (SGPT), AST (SGOT)
m.Response Follow -up: After initiation of Anti -PD-1 therapy, subjects will be assessed for clinical response according to routine care guidelines.   Patients who
are removed from therapy for reasons other than progressive disease will be followed according to standard of care procedures  until disease progression.   Patients
who discontinue study therapy in the absence of progressive disease to pursue alternative therapies will also be followed according to standard of care procedures
until disease progression.  Data from any response evaluations performed while the subject remains onstudy will be collected for research purposes.
n.Please see Section 8.4  for additional details.
o.Beginning as early as 14 days after the subject ’s last DC vaccine, subjects will commence treatment with Pembrolizumab (Anti -PD-1) as per standard of care.
The timing of pembrolizumab administration will be at the discretion of the physician investigator.   Treatment will be administered per the FDA approved
package insert and will not be drive n by protocol requirements .
p.T
he end of study visit will occu r when the last immune monit oring blood sample is collected ~ 30 weeks after  the 1st DC Vaccine (Day 1).  If the subject is
prematurely discontinued for any reason (e.g. Investigator discretion, Subject withdrawal of consent , etc), this must be documented appropriately and an En d
o
f Study Visit should be performed at the time of discontinuation .
q.Biopsy to be collected  after the last DC vaccine dose and prior to beginning Anti -PD-1 therapy .
r.Please refer to Sections 8.6 and 11 for additional information on response assessments.
s.The End of Treatment Visit will occur ~10 -28 days after the last DC Vaccine.  However this visit and associated study procedures must also occur prior  to
administration of Anti- PD-1 therapy.  Anti -PD-1 therapy may commence as early as 14 days after the subject’s last DC Vaccine.
t.If a subject dose not receive pembrolizumab per routine care post -DC Vaccine, either at the physician -investigator’s discretion or per subject decision, the
subject will complete their End of Study Treatment Visit as scheduled and continue to have their im mune monitoring samples collected per protocol.  However
the subject would not undergo the Post -Anti-PD-1 Therapy Visit #1 or Visit #2.  The subject would then complete the End of Study visit once immune monitoring
sample collection is completed per protoc ol requirements.
u.Must be performed within 14 days prior to physician -investigator  confirmation of eligibility .
v.Study timepoints will be calculated from the 1st DC Vaccine Infusion (i.e. Day 1 , also known as Week 1). Thus, the 2nd DC Vaccine Infusion is planned for  6
f
ull weeks after Day 1/Week 1  at ~Day 43 (i.e. the e nd of Week 6 and the beginning of Week 7).   Similarly, the 3rd DC Vaccine Infusion is planned for 12
full weeks after Day 1/Week 1 at ~Day 8 5 (i.e. the end of Week 12 and the beginning of Week 13).  This same principle applies to the timing/identification of
immune monitoring sample collection .
w.T
ests/procedures used to evaluate the subject’s eligibility to participate must be performed prior to physician -investigator confirmation of eligibility  and
within 28 days prior to physician- investigator confirmation of eligibility unless otherwise specified .  Tests/procedures performed for screening/enrollment
which  also fall within  the 14 day window required for Pre -Treatment evaluations may be used to fulfill this additional study requirement and do not need t o
b
e repeated unless clinically indicated.
DC Vaccine for Melan oma Page 22 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 11.0 CRITERIA FOR RESPONSE (RECIST Criteria  v1.1) 
11.1 Tumor Measurement 
Measurable disease:  the presence of at least one measurable lesion.  If the measurable disease is 
restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.  
Measurable lesions: lesions that can be accurately measured in at least one dimension with the 
longest diameter ≥ 2.0 cm.  With a spiral CT scan, the lesion must be ≥ 1.0 cm in at least one 
dimension. 
Non-measurable lesions : all other lesions, including small lesions (longest diameter < 2.0 cm with 
conventional techniques or <1.0 cm with spiral CT scans) and other non- measurable lesions. These 
include: bone lesions; leptomeningeal disease; ascites; pleural/pericardial effusion; inflamma tory 
breast disease; lymphangitis cutis/pulmonis; abdominal masses that are not confirmed and followed 
by imaging techniques; and cystic lesions.  
A
ll measurements should be recorded in metric notation, using a ruler or calipers.  All baseline 
evaluations should be performed as close as possible to the treatment start and never more than 4 
weeks before the beginning of the treatment.  
T
he same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. 
C
linical lesions will only be considered measurable when they are superficial (e.g., skin nodules, 
palpable lymph nodes).  For the case of skin lesions, documentation by color photography including 
a ruler to estimate the size of the lesions is recommended.  
11.2 Baseline Documentation of Target and Non-target Lesions 
A
ll measurable lesions up to a maximum of 10 lesions representative of all involved organs should 
be identified as target lesions and will be recorded and measured a t baseline.  
T
arget lesions should be selected on the basis of their size (lesions with the longer diameter) and 
their suitability for accurate repetitive measurements (either by imaging techniques or clinically).  
A
 sum of the longest diameter (LD) for all target lesions will be calculated and reported as the 
baseline sum LD.  The baseline sum LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.  
A
ll other lesions (or sites of disease) should be identified as non -target lesions and should also be 
recorded at baseline.  Measurements are not required and these lesions should be followed as 
“present” or “absent.”  
DC Vaccine for Melan oma Page 23 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 11.3 Response Criteria 
11.3.1 Evaluation of T arget L esions  
C
omplete response (CR) −disappearance of all target lesions.  
P
artial response (PR) −at least a 30% decrease in the sum of the LD of the target lesions 
taking as reference the baseline sum LD.  
P
rogression (PD) −at least a 20% increase in the sum of the LD of the target lesions taking 
as reference the smallest sum LD recorded since the treatment started or the appearance of 
one or more new lesions. 
S
table disease (SD) −neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD taking as refer ences the smallest sum LD since the treatment started.  
11.3.2 Evaluation of Non- target L esions  
C
omplete response (CR) −disappearance of all non -target lesions and normalization of 
tumor marker level.  
No
n-complete response (non- CR)/non -progression (non- PD)−persi stence of one or more 
non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.  
P
rogressive disease (PD) −appearance of one or more new lesions.  Unequivocal 
progression of existing non- target lesions.  Although a clear progression of non- target 
lesions only is exceptional, in such circumstances, the opinion of the treating physician 
should prevail and the progression status should be confirmed later on by a review panel 
(or principal  investigator). 
11.4 Evaluation of Best Overall Response 
T
he best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started). In general, the patient’s best response assignment will depend 
on the achievement of both measurement and confirmation criteria. 
Target 
lesions  Non-target lesions  New lesions  Overall response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
P
atients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “symptomatic 
DC Vaccine for Melan oma Page 24 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. deterioration.”  Every effort should be made to document the objective progression even after 
discontinuation of treatment. 
I
n some circumstances, it may be difficult to distinguish residual disease from normal tissue.  When 
the evaluation of complete res ponse depends upon this determination, it is recommended that the 
residual lesion be investigated (fine needle aspirate/biopsy) before confirming the complete response status.  
11.5 Confirmation 
T
o be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat 
studies that should be performed no less than 4 weeks after the criteria for response are first met.  
I
n the case of SD, follow -up measurements must have met the SD criteria at least once after study 
entry at a minimum interval of 8-12 weeks.  
12.0 EARLY WITHDRAWAL OF SUBJECTS 
S
ubjects who enroll but do not receive DC Vaccine #1  will be prematurely discontinued from the study, 
will not be followed  (with the exception of monitoring of adverse events felt to be related to research 
procedures) , and will be replaced in the study.  Reasons for premature discontinuation prior to receipt of  
DC Vaccine #1  may  include, but are not limited to the following: 
•Screen failures
•The judgment of the principal investigator that the patient is too ill to continue if this occur s
p
rior to  the vaccine dose.
•Pregnancy
•Technical difficulties are encountered in the manufacturing process that preclude generation of
a vaccine dose that meets all Quality Control criteria.
•If a subject develop s a condition that precludes treatment  after eligibility confirmation by
physician- investigator but before administrative of the vaccine dose. This will be done at the
judgment of the PI, and could include for example, the occurrence of an intercurrent illness ,
s
ignificant and rapid progression of malignancy requiring alternative treatment, or a serious
adverse event.
•Patient withdraws consent
•Termination of the study
P
atients may also  be discontinued from Protocol Therapy for any of the following reasons:  
•Patient withdraws consent
•The PI decides to remove the patient from the study  (i.e. for non- compliance with the protocol
or rapid clinical progression requiring urgent therapeutic intervention ).
•Terminat ion of the study
•Patients who develop DLT (as defin ed in Section 9.1 )
•Patients who develop an allergic reaction to the dendritic cell vaccine (mDC3/8  vaccines).
•Pregnancy
I
f a subject is discontinued from Protocol Therapy for any reason other than withdrawal of consent, they 
will remain in protocol follow -up for 30 days after the last mDC3/8  Vaccine to monitor for any potential 
DC Vaccine for Melan oma Page 25 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. adverse events.  During this 30 day follow -up period, immune monitoring samples will continue to be 
collected and subjects may be treated per routine care at the discretion of their treating physician.   
13.0 SAFETY AND ADVERSE EVENTS 
13.1 Definitions 
Adverse Eve nt 
An adve rse e vent (AE) is any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related .  Intercurre nt illnesses or injuries should be 
regarded as adverse eve nts. 
S
erious  Adverse Eve nt 
Adverse eve nts are classified as serious or non-serious.  A serious ad verse event is any AE that 
is:  
•fatal
•life-thr eatening
•requires or prolongs hospi tal stay
•le
ads to a persistent or significant disability or incapacity or substantial disruption of the
ability to conduct normal life functions
•a conge nital anomaly or birth  defect
•an importa nt medical event
N
ote that hospitalizations that meet the following criteria should not be reported as serious 
adverse events:  
•Routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition, such as preplanned study visits and preplanned hospitalizations
for study procedures or treatment administration
•Elective or pre -planned treatment for a pre- existing condition that is unrelated to the
indication under study and has not worsened since signing the informed consent
•Social reasons and respite care in the absence of any deterioration in the patient’s generalcondition
No
te: Treatment on an emergency outpatient basis that does not result in hospital admission 
and involves an event not fulfilling any of the definitions of a SAE given above is not a serious adverse event.   
I
mport a
nt medi cal eve nts are those that may not be immedi ately life threatenin g, but are c learly 
of major  clinical significan ce.  They may jeopardize the patient, and may require intervention to 
prevent one of the other se rious  outcomes noted above.  F or example, drug overdose or abuse, a 
seizure that did not result -in patient hospitalization, or intensive treatment of bronchospasm in an 
emergency department would typically be considered serious.  
Al
l advers e events that do not meet any of the c riteria for se rious  should be regarded as non-
serious ad verse  events . 
DC Vaccine for Melan oma Page 26 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. Unanticipated Adverse Device Effect  
Unanticipated adverse device effect means any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or associated with, a device, if that effect, problem, 
or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, s afety, or welfare 
of subjects.  
U
nexpected adverse events  
An adverse event is considered unexpected if the event , and  the severity  (grade)  and/or frequency  
of the event,  is not described in the investigator brochure or protocol.  Please refer to the 
investigator brochure for additional detail related to severity and/or frequency of a particular 
event.  
R
elated adverse events  
An adve rse event is considered related to participation in the research if there i s a reasonable  
possibilit y that  an event was caused by an investigational product, intervention, or research-
required procedures.  For the  purposes of  this study, "reasonab le poss ibility" means the re is 
evidence to sugge st a ca usal relation ship.  The relationship of the event to the study will be 
classified as possibly related, probably related, and definitely related.  
•Possibly Related: There is some evidence to suggest a causal relationship; however, other
factors may have contributed to the event.
•Probably Related: There is evidence to suggest a causal relationship, and the influence ofother factors is unlikely.
•Definitely Related: There is clear evidence to suggest a causal relationship, and otherpossible contributing factors can be ruled out.
Ad
verse Eve nt Repor ting P eriod 
For this study, collection of AEs will begin at the time of the first apheresis procedure 
(Apheresis #1) and continue until subject discontinuation or the End of Study Visit.  
If
 a subject is taken  off study within 30 days of study treatment, any event that is determined to be 
probably or definitely related regardless to time at which it occurs after infusion (s), will be reported 
to the Sponsor Medical Director for assessment.  
P
reexisting Condition /General Physical Examination Findings  
A preexisting condition is one that is present at the start of the  Adverse Event Reporting Period. 
All clinically significant abnormalities should be recorded as a preexisting condition on the medical 
history eCRF.  During the course of the study, a preexisting condition should be recorded as an 
adverse event if the frequency, intensity, or the character of the condition worsens.  Preexisting 
conditions that improve should also be recorded appropri ately.  
Abno
rmal Laborato ry Va lues 
A clinical labo ratory abnormalit y should be documented as an adve rse event if any one of the 
following conditions is met:  
•The labo ratory abnormality is not  other wise re futed b y a  rep eat  test  to  c onfirm the
abnormality
•The abnormality suggests a dis ease and/or organ tox icity
•T
he abnormality is of a degree that re quires acti ve management;  e.g. cha nge of dose,
DC Vaccine for Melan oma Page 27 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. disconti nuation of  the drug, more frequent follo w-up a ssessments,  further diagnostic 
invest igation, e tc. 
L
aboratory abnormalities that meet the criteria for Adverse Events should be followed until they 
have returned to normal or an adequate explanation of the abnormality is found. When an abnormal 
laboratory or test result corresponds to a sign/symptom of an already reported adverse event, it is 
not necessary to separately record the lab/test result as an additional event. Laboratory abnormalities that do not meet the definition of an adverse event, should not be reported as adverse 
events. Whenever possible, a diagnosis, rather than a symptom should be provided (i.e. anemia 
instead of low hemoglobin).   
13.2 Recording of Adverse Events 
S
afety will be assessed by monitoring and recording potential adverse effects of the treatment using 
the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 at each study visit. 
Patients will be monitored by medical histories, physical examinations, and blood studies to detect potential toxicities from the treatment.  If CTCAE grading does not exist for an adver se event, the 
severity of mild, moderate, severe, life -threatening, and death, corresponding to Grades 1 -5, will be 
used whenever possible. Subjects will be monitored by medical histories, physical examinations, and blood studies to detect potential toxici ties from the treatment.  
A
t each contact with the subject, the investigator must seek information on adverse events by non -
directive questioning and, as appropriate, by examination. Adverse events also may be detected when they are volunteered by the subject during the screening process or between visits, or through physical examination, laboratory test, or other assessments. Information on all adverse events should 
be recorded in the source documentation.  All clearly related signs, symptoms, and abnormal  
diagnostic procedures results should be recorded in the source document, though should be grouped 
under one diagnosis. To the extent possible, adverse events should be recorded as a diagnosis and 
symptoms used to make the diagnosis recorded within the diagnosis event.  Do not list symptoms  
separately  if a diagnosis can be assigned.  The safety team may require events be reported separately 
if they occur as SAEs (or in the context of a SAE) even if they can also be considered a constituent of another AE. 
A
ll adverse events occurring during the adverse event reporting period (defined in Section 13.1 
above) must be recorded.  Adverse events that begin in Primary Follow -up and are ongoing at the 
time the subject enters the Post -DC Vaccine Surveilliance phase of the study will continue to be 
followed until: a) the adverse event resolves; b) the subject discontinues participation (i.e. End of 
Study); or c) there is a change in the adverse event that would normally require the even t be 
captured as a new event (i.e. change in attribution). Please refer to the CRF Completion Guidelines (CCG) for specific instructions on data entry.  
A
s much as possible, each adverse event should be evaluated to determine:  
1.The severity grade (CTCAE Grade 1 -5)
2. Its duration (s tart and end dates)
3.Its relationship to the study treatment- [Reasonable possibility that AE is related: No
(unrelated/ not suspected) or Yes (a suspected adverse reaction)].  If yes (suspected) - is the
e
vent possibly, probably or definitely related to the investigational treatment?
4.Expectedness to study treatment - [Unexpected - if the severity and/or frequency is not
described in the investigator brochure or protocol].
DC Vaccine for Melan oma Page 28 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 5.Action taken with respect to study or investigational treatmen t (none, dose adjuste d,
t
emporarily interrupted, permanently discontinued, unknown, not applicable)
6.Whether medication or therapy taken (no concomitant medication/non- drug therapy,
concomitant medication/non -drug therapy)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 13.1.
A
ll adverse events should be treated appropriately. If a concomitant medication or non -drug therapy 
is given, this action should be recorded.  Once an adverse event is detected, it should be followed 
until its resolution or until it is judged to be permane nt, and assessment should be made at each 
visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the 
study treatment, the interventions required to treat it, and the outcome.   
A
dverse events that occur concurrently with the progression of malignancy but that are not related 
to disease progression (i.e. deep vein thrombosis or hemoptysis) will be reported as an adverse event as described above.  Progression of malignancy resulting in death should be reported as a  
serious adverse event.  
S
erious adverse events that are still ongoing at the end of the adverse event reporting period must 
be followed to determine the final outcome.  Any serious adverse event that occurs after the adverse event reporting period and is  considered to be possibly related to the study treatment or study 
participation, should be promptly recorded and reported. 
13.3 Reporting of Serious Adverse Events 
E
very SAE  and UADE , regardless of suspected causality , occurring during the adverse event 
reporting period defined in Section 13.1 must be reported to the Sponsor Team  within 24 hours of 
learning of its occurrence. The original SAE notification may take place by email to meet the 24 hour reporting window.   
Wi
thin 3 business days of initial knowledge of the event, the investigator must submit a complete 
SAE form to the Sponsor along with any other diagnostic information that will assist the understanding of the event.  The Investigator will keep a copy of this SAE Form on file at the study site.   
Ne
w or follow- up information on SAEs should be promptly reported as updates become available. 
A
t a minimum follow -up SAE Forms should be submitted: 
•Within 1 week of ICU admission or any life- threatening even t
•Wi
thin 2 weeks of hospital discharge
F
ollow-up information should be submitted as an amendment to the initial SAE form, and should 
include both the follow -up number and report date.  The follow -up information should describe 
whether the event has resolved or continues, if there are any changes in assessment, if and how it was treated, and whether the patient continued or withdrew from study participation.    
R
eport serious adverse events by email to:  
Attention: Clinical Safety Manager or designee  
Center for Cellular Immunotherapies  
University of Pennsylvania  
DC Vaccine for Melan oma Page 29 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. A
t the time of the initial notification, the following information should be provided: 
•Study identifier
•Subject number
•A description of the event
•Date of onset
•Current subject status•Whether study treatment w as
discontinued
•The reason the event is classified  as
s
erious
•Investigator assessment of th e
a
ssociation between the event and study
treatment
•Expectedness relative to investigational
product(s)
13.3.1 Investigator Reporting: Local Regulatory Review Committees 
R
eport events to local regulatory review committees per institutional requirements.  
13.4 Pregnancies 
T
o ensure patient safety, each pregnancy occurring while the patient is on study treatment must be 
reported to protocol sponsor within 24 hours of learning of its occurrence. The pregnancy should 
be followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.  If a pregnancy occurs on study, this will be reported as an SAE 
using an SAE Report Form. 
P
regnancy outcomes must be collected for the female partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes should 
be obtained from the mother. 
13.5 Protocol Exceptions/Deviations 
E
xception:  
A one time, intentional  action or process that departs from the IRB-approved study protocol, 
intended for one  occurrence. If the action disrupts the study progress , such that the study design or 
outcome (endpoints)  may be compromised, or the action compromises the safety and welfare of 
study subjects , advance  documented approval from the Regulatory Sponsor  and local regulatory 
review committees per institut ional guidelines is required.  Approval from the Regulatory Sponsor 
must be received prior to submission to local regulatory review committees for approval.  
D
eviation: 
A one time, unintentional  action or process that departs from the approved study protocol, 
involving one incident and identified retrospectively , after the event occurred. If the impact on 
the protocol disrupts the study design , may affect the outcome (endpoints)  or compromises the 
safety and welfare of the subjects, the deviation must be reported to the Regulatory Sponsor  within 
10 business days of PI knowledge , and to local regulatory review committees per institutional 
guidelines. Acknowledgement from the Regulatory Sponsor must be received prior to submission 
to local regulatory review committees.    
DC Vaccine for Melan oma Page 30 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. Other deviations should be appropriately documented per site policies/procedures (such as a subject 
missing a visit is not an issue unless a critical/important treatment or procedure was missed and 
must have been done at that specific time).  
I
nclude the following information on the Sponsor supplied exception/deviation form:  protocol 
number, subject study number, comprehensive description of the exception/deviation from the 
protocol, rationale , and corrective and preventative action plan (deviations only) .  Ensure all 
completed exc eption/deviation forms are signed by the Principal Investigator (or physician sub-
investigator) and submitted to the Sponsor Project Manager for review.    
A
ttention: Sponsor Project Manager  
Center for Cellular Immunotherapies (CCI)  
University of Pennsylvania 
O
nce approval of the exception request or acknowledgement of the deviation has been granted by 
the Regulatory Sponsor, the exception or deviation will be submitted to all applicable committees 
for review and approval /acknowledgement per institutional guidelines .  
13.6 Medical Monitoring 
It is the responsi bility of the Principal Investigator to oversee the safety of the study at the clinical 
site.  This safety monitoring  will include careful assessment  and appropriate re porting of adve rse 
events as noted above.  Medical monitoring will include  a regular asse ssment of the  number and 
type of se rious adve rse events. 
13.7 Study Stopping Rules  
T
his trial will be paused if:  
•Any death that may be related to the investigational product.
•DLT is observed in 2 out of the first 2 subjects, 3 out of the first 4 subjects, 4 out of the first 7,
5 out of the first 10, and 6 at any time .
T
he study may be discontinued at any time by the IRB, the Sponsor, the FDA, or other government 
agencies as part of their duties to ensure that research subjects are protected.  
14.0 STATISTICAL CONSIDERATIONS  
A
pproximately 12 evaluable patients will be enrolled in this study.  Patients who fail apheresis or who do 
not receive vaccine due to other reasons will not be considered evaluable and will be replaced.  
The primary end point of the study is to determine the post -vaccine immune response based on measuring 
increased numbers of peptide -specific CD8 T cells as calculated by the tetramer assay. For each peptide, 
the tetramer assay is performed on blood samples obtained at the indicated time points. Data are presented 
as the percentage of CD8+ T cells positive for tetramer binding based on gating variables set using the 
iMASC reagent kit (Beckman Coulter). The lower limit of detection (LLD) is 0.03% based on the  
acquisition of 100,000 gated events in the lin- CD8+ gate. The HIV gag HLA -A*0201 restricted peptide 
(SLYNTVATL) is used as the non -binding control peptide. Each sample is stained with the HIV gag 
tetramer and the number of HIV gag positive CD8+ T cells is  subtracted from each experimental point (ref 
24). The mean and SD at baseline is obtained for each patient. Based on our prior experience, the expected 
DC Vaccine for Melan oma Page 31 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. analytical CV (standard deviation/mean) is 10%. A positive tetramer response is defined as an increase 
greater than 3SD above the baseline value. For each gp100 peptide, the proportions of tetramer response 
(positive or negative) and the associated 90% exact confidence intervals (CI) will be reported for each time 
point. With 12 patients, the width of the 9 0% exact CI will be no more than 25% away from the observed 
proportions. Tetramer counts (percentage of CD8+ T cells positive for tetramer binding) are expected to be 
approximately Gaussian on the original or a transformed scale (e.g., log transformation) .  Linear mixed 
models will be used to describe the change in counts by time, dose and the time by dose interaction and 
pattern over time will be examined graphically.  Dose is treated as a fixed effect as the doses to be administered cover the range about which conclusions will be drawn.  We will explore whether Time should 
be treated as a random effect, as the time points represent a sample from an ongoing process.  In addition, 
clustered logistic regression will be used to model the probability of tetrame r positive versus negative by 
time, dose and time by dose interaction.  These models are intended to be descriptive, and no preliminary data exist with which estimate longitudinal trends, so no power calculation is attempted.    
T
he primary endpoint will also include evaluating the safety and tolerability of the mature dendritic cell 
vaccine using proportions and confidence intervals . Adverse events will be tabulated by grades and body 
system.    
A
dditional correlative assays will be performed (Elispot an d Cr51 release); however, these data will be not 
be used to determine the primary end point but be used as surrogate assays for the tetramer assay to evaluate 
the functionality of gp100 peptide induced CD8+ T cells. These assays will be performed using CD8+ T 
cells from baseline and post- vaccination blood samples. A positive elispot assay is defined as an increase 
greater than 3 SD above the baseline value. A positive Cr51 assay is defined an increase in specific lysis > 15% above background at effector: target ratio of 5:1.  
F
or the secondary objective, clinical response rate will be computed with 90% CI. Time to progression 
(TTP) will be described by Kaplan- meier method and median survival time and the associated 90% CI will 
be reported. TTP is defined as time from the first DC dose administration to date of first documented disease 
progression. Patients without disease progression will be censored at time of last disease evaluation. 
Patients who die without evidence of progression will be censored at date  of death. Regulatory T cells 
(Treg) are defined as CD4+CD25+foxP3+ (triple positive) cells. At the indicated time points, the percentage 
of Treg cells is determined by 3 color flow cytometry. The depletion of Treg is defined as follows [ (Treg 
baseline  – Treg nadir )/ Treg baseline x 100= % depletion] and will be analyzed as a continuous variable.    
15.0 DATA HANDLING AND RECORDKEEPING  
15.1 Confidentiality 
I
nformation about study subjects will be kept confidential and managed according to the 
requirements of the  Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following: 
•Wha t prote cted healt h information (PHI ) will be c ollected from subjects in this stud y
•W
ho will ha ve access to that information and why
•Who will use or dis close that info rmation
•The rig hts of a  research subject to re voke  their authorization for use  of th eir PHI.
I
n the event that a subject  revokes authorization to coll ect or use  PHI, the  invest igator, by 
regulation, re tains  the ability to use a ll information  coll ected  prior to the revocation of patient 
authorization.   For subjects  that have revoked authorization to collect or use PHI, atte mpts 
DC Vaccine for Melan oma Page 32 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. should be made  to obtain pe rmission  to collect at least vital status (i.e. that the subject  is alive ) at 
the end of their sche duled stu dy pe riod. 
15.2 Source Documents  
Source da ta is all infor mation, original r ecords of clinical findi ngs, observations, or other activities 
in a cli nical trial nece ssary for the reconstru ction a nd evaluation of the trial.  Sourc e data are 
contained in source documents. Exa mples of these  original documents, and da ta records includ e: 
hospital  records,  clinica l  and  of fice  cha rts,  laboratory notes,  memo randa,  patients’ dia ries or 
evaluation  chec klists, pha rmacy dis pensing reco rds, record ed da ta from a utomated ins trume nts, 
copies  or transcr iptions certifi ed after ve rification as being accurate and c omplete, m icrofiches, 
photog raphic n egative s, microfilm or magnetic medi a, x-r ays, patient  fi les, and records kept at the 
pharmacy, at the laboratories, and at medi co-techni cal depa rtments involved in t he clinical t rial. 
T
he i
nvestigator must maintain source documents for each subject in the study, consisting of case 
and visit notes (hospital or clinical medical records) containing demographic and medical 
information, laboratory data, and the results of any other tests or assessments. All information 
recorded on the eCRFs must be traceable to source documents in the patient’s file. The investigator 
must also keep the original signed informed consent form, and a signed copy must be given to the 
patient.  
15.3 Case Report Forms 
T
he study case report form (CRF) is the primary data collection instrument for the study. All  
data requested on the CRF must be recorded. All entries will be entered into an electronic  
data capture system (EDC). The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, accurate, and that entry and updates are pe rformed in a timely 
manner.  
15.4 Records Retention 
It is the I nvestigator’s responsibility to retain study essential documents for at least 2 years after 
the last approval of a marketing application in their country and until there are no pending or contempl ated marketing applications in their country or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the investigational product.  These documents may be retained for a longer period if required.   
16.0 STUDY MONITORING, AUDITING, AND INSPECTING  
16.1 Study Monitoring Plan 
T
his study will be monitored according to the Sponsor Data and Safety Monitoring Plan.  
I
nterim Monitoring Visits will be conducted during the course of the study. The Monitors will 
assure that submitted data are accurate and in agreement with source documentation; verify that investigational products are properly stored and accounted for; verify that subject consent for study 
participation has been properly obtained and documented; confirm that research sub jects entered 
into the study meet inclusion and exclusion criteria; and assure that all essential documentation 
DC Vaccine for Melanoma 
Protocol Version 9.08-10-2021 Page 33 of 38 
required by Good Clinical Practices (GCP) guidelines are approp1iately filed. At the end of the 
study, Monitors will conduct a close-out visit and will advise on storage of study records and 
disposition of unused investigational products. 
The investigator will allocate adequate time for such monitoring activities. The Investigator will 
also ensure that the monitor or other compliance reviewer is given access to all the above noted 
study-related documents and study related facilities (e.g. phrumacy, diagnostic laborato1y, etc.), 
and has adequate space to conduct the monitoring visit. 
16.2 Auditing and Inspecting 
The investigator will permit study-related monitodng, audits, and inspections by the IRB, the 
Sponsor, government regulato1y bodies, and University compliance groups. The investigator will 
ensure the capability for inspections of applicable study-related facilities ( e.g. phrumacy, diagnostic 
laboratory, etc.). 
Pa1ticipation as an investigator in this study implies acceptance of potential inspection by 
government regulatory authorities and applicable University compliance offices. 
The Plincipal Investigator must notify the Sponsor in real-time if an audit/inspection notification 
is received. 
17.0 ETHICAL CONSIDERATIONS 
This study is to be conducted according to US and international standru·ds of Good Clinical PI·actice (FDA 
Title 21 prut 312 and International Conference on Ha1monization guidelines), applicable government 
regulations and Institutional reseru·ch policies and procedures. 
This protocol and any amendments will be submitted to a properly constituted independent Institutional 
Review Board (IRB), in agreement with local legal presc1iptions, for fo1mal approval of the study 
conduct. The decision of the IRB concerning the conduct of the study will be made in writing to the 
investigator and a copy of this decision will be provided to the sponsor before commencement of this study. 
All subjects for this study will be provided a consent fo1m describing this study and providing sufficient 
info1mation for subjects to make an inf01med decision about their pruticipation in this study. This consent 
fo1m will be submitted with the protocol for review and approval by the IRB for the study. The 
formal consent of a subject, using the !RB-approved consent f01m, must be obtained before that subject is 
submitted to any study procedure. 
The protocol is listed on clinicaltrials.gov. 
18.0 STUDY FINANCES 
18.1 Funding Source 
CONFIDENTIAL 
This protocol is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor. 
DC Vaccine for Melanoma 
Protocol Version 9.08-10-2021 
Parker Institute for Cancer Immunotherapy 
18.2 Conflict of Interest Page 34 of38 
All University of Pennsylvania Investigators will follow the University of Pennsylvania Policy on 
Conflicts of Interest Related to Research. 
18.3 Patient Stipends or Payments 
There is no patient stipend/payment for pruticipation in this protocol. 
19.0 PUBLICATION PLAN 
Publication of the results ofthis t.Iial will be governed by University of Pennsylvania policies. Neither the 
complete nor any part of the results of the study caITied out under this protocol will be published or passed 
on to any third pruty without the consent of the Sponsor. Any investigator involved with this study is 
obligated to provide the Sponsor with complete test results and all data de1ived from the study. 
CONFIDENTIAL 
This protocol is the property of the University of Pennsylvania. Do not disclose or use except as authorized in writing by the study sponsor. 
DC Vaccine for Melan oma Page 35 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. 20.0 REFERENCES 
1: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 
Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. PubMed PMID: 26742998. 
2:
 Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, 
Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, 
Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C,  
Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, 
Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma.  N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 
Jun 5. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290. PubMed PMID: 20525992; 
PubMed Central PMCID: PMC3549297. 
3:
 Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, 
Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann 
KF, Hassel JC, Ma io M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, 
Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed  
after anti -CTLA -4 treatment (CheckMate 037): a randomised, controlled, 
open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2035 Mar 18. PubMed PMID: 25795410. 
4:
 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, 
Schach ter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, 
Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, 
Kirkwood JM, Wolchok JD, E ggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, 
Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice 
chemotherapy for ipilimumab- refractory melanoma (KEYNOTE -002): a randomised, 
controlled, phase 2 trial. Lancet Oncol. 2015 Aug;16(8):908-18. doi: 
10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23. PubMed PMID: 26115796. 
5:
 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R,  
Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D,  
Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J,  Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved 
survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 
2011 Jun 30; 364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. PubMed 
PMID: 21639808; PubMed Central PMCID: PMC3549296. 
6
: Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski  
D, Lichinitser M, Dummer R, Grange F, Mortier L, Chia rion-Sileni V, Drucis K,  
Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, 
Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.  
Improved overall survival in melanoma with combined dabrafenib and trame tinib. N  
Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16. 
PubMed PMID: 25399551. 
7:
 Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, 
Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz -Merino L, Dutriaux C, 
DC Vaccine for Melan oma Page 36 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, 
Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)- mutant  
melanoma (coBRIM): updated efficacy results from a randomised, double-bli nd, 
phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30. PubMed PMID: 27480103. 
8:
 Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination 
chemotherapy with or without immunotherapy in metastatic melanoma: a  
meta -analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001 
Feb;11(1):75-81. PubMed PMID: 11254118. 
9:
 Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, 
Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III 
multicenter randomized trial of the Dartmouth regimen versus dacarbazine in 
patients with metastatic melanoma. J Clin Oncol. 1999 Sep;17(9):2745-51. PubMed 
PMID: 10561349. 
10:
 Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J,  
Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis  
of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 
Jul;17(7):2105-16. PubMed PMID: 10561265. 
11:
 Morton DL, Eilber FR, Joseph WL, Wood WC, Trahan E, Ketcham AS. Immunological 
factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann  
Surg. 1970 Oct;172(4):740-9. PubMed PMID: 5272336; PubMed Central PMCID: 
PMC1397284. 
12:
 Golub SH, Morton DL. Sensitisation of lymphocytes in vitro against human 
melanoma -associated antigens. Nature. 1974 Sep 13;251(5471):161-3. PubMed PMID: 
4421563. 
13:
 Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins 
PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the 
human melanoma antigen gp100 by tumor- infiltrating T lymphocytes associated with  
in vivo tumor regression. J Immunol. 1995 Apr 15;154(8):3961-8. PubMed PMID: 
7706734. 
14:
 Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. The use 
of melanosomal proteins in the immunotherapy of melanoma. J Immunother. 1998 Jul;21(4):237-46. Review. PubMed PMID: 9672845. 
15:
 Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens 
recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer.  
2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Review. PubMed PMID: 24457417. 
1
6: Marincola FM, Hijazi YM, Fetsch P , Salgaller ML, Rivoltini L, Cormier J,  
Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the melanoma- associated antigens MART -1 and gp100 in metastatic melanoma cell  
lines and in in situ lesions. J Immunother Emphasis Tumor Immunol. 1996 
DC Vaccine for Melan oma Page 37 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. May;19(3):192-205. PubMed PMID: 8811494. 
17:
 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, 
Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR,  
Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic 
evaluation of a synthetic peptide vaccine for the treatment of patients with  
metastatic melanoma. Nat Med. 1998 Mar;4(3):321 -7. PubMed PMID: 9500606; PubMed 
Central PMCID: PMC2064864. 
18:
 Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, 
Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. 
Immunization using autologous dendritic cells pulsed with the melanoma- associated  
antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 
2005 Nov 1;11(21):7692-9. PubMed PMID: 16278389. 
19:
 Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter 
S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor -associated antigens in melanoma patients.  
Nat Med. 1999 Jun;5(6):677-85. PubMed PMID: 10371507. 
20:
 Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, 
Hunt DF, Engelhard VH, Slingluff CL Jr. Shared epitopes for HLA- A3-restricted  
melanoma -reactive human CTL include a naturally processed epitope from  
Pmel -17/gp100. J Immunol. 1996 Dec 1;157(11):5027-33. PubMed PMID: 8943411. 
21:
 Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, 
Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K,  Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, 
Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G,  
Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner 
SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals  
frequent PREX2 mutations. Nature. 2012 May 9;485(7399):502-6. doi: 10.1038/nature11071. PubMed PMID: 22622578; PubMed Central PMCID: PMC3367798. 
22:
 Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, 
Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP. Cancer immunotherapy. A 
dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen -specific T cells. Science. 2015 May 15;348(6236):803-8. doi: 
10.1126/science.aaa3828. Epub 2015 Apr 2. PubMed PMID: 25837513; PubMed Central PMCID: PMC4549796. 
23:
 Mellm an I, Steinman RM. Dendritic cells: specialized and regulated antigen  
processing machines. Cell. 2001 Aug 10;106(3):255-8. Review. PubMed PMID: 
11509172. 
24:
 Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender 
A, Maczek C, Schrei ner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, 
Kämpgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte- derived dendritic cells expands specific cytotoxic T cells and induces  
DC Vaccine for Melan oma Page 38 of 38
Protocol Version 9 .08-10-2021
C
ONFIDENTIAL  
This protocol  is the property of the University of Pennsylvania.  Do not disclose or use except as authorized in writing by the study spons or. regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999 Dec  
6;190(11):1669-78. PubMed PMID: 10587357; PubMed Central PMCID: PMC2195739. 
25:
 Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, 
Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J. 
Immune and clinical responses in patients with metastatic melanoma to CD34(+)  
progenitor-derived dendritic cell vaccine. Cancer Res. 2001 Sep 1;61(17):6451-8.  PubMed PMID: 11522640. 
26:
 Nishikawa H, Sakaguchi S. Regulatory T cells in c ancer immunotherapy. Curr  
Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14.  
Review. PubMed PMID: 24413387. 
27:
 Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity 
in a randomized trial of patients receiving active specific immunotherapy with  
melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 1990 Sep 1;50(17):5358-64. PubMed PMID: 2143687. 
28:
 Steinman RM. Decisions about dendritic cells: past, present, and future. Annu 
Rev Immu nol. 2012;30:1-22. doi: 10.1146/annurev-immunol-100311-102839. Epub 2011 
Nov 17. Review. PubMed PMID: 22136168. 
29:
 Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: 
enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists  
of T cell activation. Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274. Review. PubMed PMID: 25810313. 
30:
 Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, 
Cornelius LA, Trinkaus KM, Lin ette GP. IL -12p70-producing patient DC vaccine 
elicits Tc1 -polarized immunity. J Clin Invest. 2013 Aug;123(8):3383-94. doi: 
10.1172/JCI68395. Epub 2013 Jul 11. PubMed PMID: 23867552; PubMed Central PMCID:  
PMC3726168. 
31:
 Weber J et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.  N Eng J 
Med 2017; 377: 1824-1835. PubMed PMID: 28891423. 